PTC Therapeutics announces Sephience granted marketing authorization by EC

PTC Therapeutics (PTCT) announced that Sephience was granted marketing authorization by the European Commission, EC, for the treatment of children and adults living with phenylketonuria, PKU. The authorization includes a broad label inclusive of all ages and disease severities. “The European approval of Sephience is a great step in our efforts to bring this safe and highly effective therapy to children and adults affected by PKU worldwide,” said Matthew Klein, M.D., Chief Executive Officer of PTC Therapeutics. “The broad label supports that potential for Sephience to address all key PKU patient segments and become the new standard of care.”